Free Trial
NASDAQ:SNGX

Soligenix Q4 2024 Earnings Report

Soligenix logo
$1.91 +0.10 (+5.52%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$1.91 0.00 (0.00%)
As of 05/27/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix EPS Results

Actual EPS
-$1.14
Consensus EPS
-$0.95
Beat/Miss
Missed by -$0.19
One Year Ago EPS
-$12.66

Soligenix Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.20 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Soligenix Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
8:00PM ET

Upcoming Earnings

Soligenix's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Soligenix Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Soligenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soligenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soligenix and other key companies, straight to your email.

About Soligenix

Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

View Soligenix Profile

More Earnings Resources from MarketBeat